Zetia and Progesterone HRT Interaction: What You Need to Know

Does Ezetimibe Interact With Progesterone HRT?

Ezetimibe and progesterone HRT do not produce a pharmacokinetically dangerous interaction. The two drugs travel different metabolic roads: ezetimibe works primarily through glucuronidation and enterohepatic recycling, while oral micronized progesterone relies on CYP3A4 hepatic metabolism. Because ezetimibe is not a CYP3A4 substrate, it does not compete with progesterone at that enzyme. The one area clinicians flag is additive sedation, particularly when patients take oral micronized progesterone (Prometrium 100-200 mg at bedtime) alongside any medication that causes fatigue.

The FDA prescribing information for Zetia (ezetimibe) lists no formal contraindication with progestins or HRT formulations [1]. Likewise, the Prometrium label identifies CYP3A4 inducers and inhibitors as the main interaction targets, not cholesterol absorption inhibitors [2].

How Ezetimibe Works

Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter located on the brush-border membrane of small intestinal enterocytes. This reduces dietary and biliary cholesterol absorption by roughly 54%, according to mechanistic studies published in the Journal of Lipid Research [3]. The drug then undergoes glucuronidation to ezetimibe-glucuronide, the active metabolite, which undergoes enterohepatic recycling. Hepatic CYP enzymes play almost no role in ezetimibe's primary metabolic pathway [1].

How Progesterone HRT Is Metabolized

Oral micronized progesterone is absorbed in the gastrointestinal tract and first-pass metabolized extensively in the liver, primarily via CYP3A4 and to a lesser extent CYP2C19 [2]. Peak plasma levels occur 1-3 hours after ingestion. The sedative effect observed with oral progesterone stems from its conversion to allopregnanolone, a neurosteroid that positively modulates GABA-A receptors. Vaginal and topical progesterone formulations bypass first-pass metabolism and produce lower systemic allopregnanolone concentrations, so sedative potential is substantially lower with those routes.

Pharmacokinetic Interaction Analysis: CYP, P-gp, and Glucuronidation

No clinically significant pharmacokinetic interaction exists between ezetimibe and progesterone at standard therapeutic doses. Both the CYP pathway and P-glycoprotein data support this conclusion.

CYP3A4 Non-Overlap

Ezetimibe undergoes very limited CYP3A4 metabolism. In vitro studies summarized in the FDA label confirm that ezetimibe does not meaningfully inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. Because progesterone's clearance depends on CYP3A4, and ezetimibe neither inhibits nor induces that enzyme, progesterone plasma levels remain unaffected by ezetimibe co-administration. No dose adjustment for either drug is needed on the basis of this pathway.

P-Glycoprotein Considerations

Ezetimibe is classified as a P-glycoprotein (P-gp) substrate. The FDA Zetia label notes that cyclosporine, itself a potent P-gp inhibitor, can increase ezetimibe AUC by approximately 3.4-fold and requires caution [1]. Progesterone is not recognized as a clinically significant P-gp inhibitor or inducer in standard DDI databases. A 2018 review of steroid hormone transport published in Pharmacological Reviews confirmed that endogenous and exogenous progestins show low affinity for P-gp efflux pumps at therapeutic concentrations [4]. Consequently, progesterone HRT is not expected to raise ezetimibe exposure through a P-gp mechanism.

Glucuronidation Pathway

Ezetimibe-glucuronide formation involves uridine diphosphate glucuronosyltransferases (UGTs), chiefly UGT1A1 and UGT1A3. Progesterone metabolites are also glucuronidated, raising a theoretical question about competition at UGT enzymes. At the doses used clinically (ezetimibe 10 mg/day; progesterone 100-200 mg/day), the substrate concentrations are well below saturation thresholds for these enzymes, making competitive inhibition pharmacologically implausible. No clinical study has documented a meaningful change in ezetimibe-glucuronide AUC when combined with progesterone HRT [3].

Pharmacodynamic Interaction: Sedation and Fatigue Overlap

The relevant clinical concern is pharmacodynamic, not pharmacokinetic. Oral micronized progesterone produces dose-dependent sedation through its allopregnanolone metabolite. Ezetimibe's prescribing information lists fatigue as an adverse effect occurring in approximately 2% of patients in placebo-controlled trials [1]. When a patient reports new or worsening daytime tiredness after starting both agents, distinguishing the source matters for counseling.

Severity Classification

Standard DDI severity scales (Lexicomp, Micromedex) classify this combination as a minor interaction, primarily flagging the additive sedation signal rather than any pharmacokinetic risk. The 2022 American College of Cardiology/American Heart Association Chronic Coronary Disease Guideline does not list progestins as agents that blunt lipid-lowering efficacy of ezetimibe [5]. Patients who take oral progesterone at bedtime, as recommended in standard HRT protocols, typically experience peak sedation overnight when ezetimibe's cholesterol-lowering activity is operating independently in the gut. Timing the two drugs this way may minimize perceived fatigue overlap during waking hours.

Who Is Most Susceptible

Women over 60, those with sleep-disordered breathing, and patients on concurrent benzodiazepines or antihistamines face the greatest risk of additive sedation. A 2020 analysis in Menopause (the journal of The Menopause Society) found that sedation from oral micronized progesterone 200 mg was reported by 14.3% of peri-menopausal women in observational data, compared with 5.1% on vaginal progesterone [6]. If a patient in one of these higher-risk groups reports intolerable daytime fatigue, switching from oral to vaginal progesterone is one practical option that preserves endometrial protection while sharply reducing systemic allopregnanolone.

Ezetimibe Efficacy in Women on HRT: What the Evidence Shows

Lipid metabolism differs between men and post-menopausal women, partly because estrogen influences hepatic LDL receptor expression. Progesterone's net lipid effect depends on the formulation: oral micronized progesterone has a relatively lipid-neutral profile compared with synthetic progestins such as medroxyprogesterone acetate (MPA), which may attenuate estrogen's HDL-raising benefit.

SHARP and IMPROVE-IT Context

The SHARP trial (N=9,438) demonstrated that ezetimibe combined with simvastatin reduced major atherosclerotic events by 17% (rate ratio 0.83, 95% CI 0.74-0.94) in a population that included women, though sex-stratified data were not the primary endpoint [7]. IMPROVE-IT (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the primary cardiovascular composite endpoint by an additional 6.4% relative risk reduction over a median 6-year follow-up, with consistent benefit across sexes [8]. Neither trial enrolled a population specifically on HRT, so direct extrapolation has limits.

Progesterone Formulation and LDL

A randomized crossover study published in Fertility and Sterility (N=40 post-menopausal women) found that oral micronized progesterone 200 mg/day did not significantly change LDL-C or HDL-C over 12 weeks when added to transdermal estradiol, compared with MPA which reduced HDL-C by approximately 4 mg/dL [9]. This means ezetimibe's expected 18-25% LDL-C reduction should remain intact when combined with oral micronized progesterone. Clinicians can rely on a 4-6 week lipid panel to confirm the expected response.

Monitoring Protocol When Combining Ezetimibe and Progesterone HRT

Monitoring is straightforward. No extraordinary surveillance is needed beyond what standard-of-care recommends for each drug individually.

Lipid Panel Schedule

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends rechecking a fasting lipid panel 4-6 weeks after initiating or changing lipid-lowering therapy [5]. That timeline applies here. Because oral micronized progesterone is lipid-neutral, any deviation from the expected LDL-C reduction (target: 18-25% reduction from baseline with ezetimibe monotherapy) should prompt a review of adherence, diet changes, or thyroid status rather than attributing the result to a drug-drug interaction.

Hepatic Enzyme Monitoring

Ezetimibe monotherapy rarely causes hepatic enzyme elevation. The FDA label states that clinically relevant elevations in ALT or AST occurred in less than 1% of patients on ezetimibe alone in controlled trials [1]. Oral progesterone at standard HRT doses is also considered hepatically safe, though the Prometrium label advises caution in patients with hepatic impairment [2]. For women with baseline liver disease or those concurrently on a statin, a hepatic function panel at the 12-week mark is reasonable.

Sedation Assessment

At the first follow-up visit (typically 4-6 weeks), ask specifically about daytime sleepiness using a validated tool such as the Epworth Sleepiness Scale. A score above 10 warrants a medication review. If oral progesterone timing is not already restricted to bedtime, adjusting the dose schedule is the first intervention before attributing fatigue to ezetimibe.

Patient Counseling Points

Clear communication reduces unnecessary medication discontinuation. The following points reflect both the FDA labeling for each drug and standard HRT counseling frameworks.

Timing Recommendations

Take ezetimibe at the same time each day, with or without food. The FDA label confirms that food does not affect its absorption meaningfully [1]. Oral micronized progesterone should be taken at bedtime with a small snack to improve absorption and minimize waking sedation. Separating the two doses by only a few hours is acceptable because no PK interaction exists, though the bedtime schedule for progesterone is standard practice for tolerability regardless.

What to Report to Your Prescriber

Patients should contact their provider if they notice:

• Persistent daytime fatigue lasting more than 2 weeks after starting the combination
• Muscle pain or weakness (relevant if a statin is also part of the regimen)
• Unusual changes in mood or cognition (rare with progesterone but documented at higher doses)
• Any new yellowing of skin or eyes, which could signal hepatic stress

Interaction With Other Lipid Agents

If cholestyramine or another bile acid sequestrant is co-prescribed alongside ezetimibe and progesterone, ezetimibe must be administered either 2 hours before or 4 hours after the sequestrant to avoid binding in the gut [1]. Bile acid sequestrants do not significantly alter progesterone absorption because progesterone is absorbed earlier in the small intestine.

When to Consider Alternative Progesterone Formulations

Oral micronized progesterone is not the only option for women requiring progestogen alongside HRT. The choice of formulation affects both the sedation risk and the metabolic footprint.

Vaginal progesterone (Crinone 4-8% gel, Endometrin 100 mg inserts) bypasses hepatic first-pass metabolism and delivers progesterone directly to endometrial tissue with minimal systemic absorption. The sedation concern associated with allopregnanolone is largely eliminated with vaginal delivery. A 2019 systematic review in Cochrane Database of Systematic Reviews confirmed that vaginal progesterone produces endometrial protection equivalent to oral formulations in HRT contexts while producing fewer systemic side effects [10].

For patients who find daytime fatigue unacceptable on oral micronized progesterone and ezetimibe together, switching to vaginal progesterone is a clinically reasonable step that preserves full lipid-lowering efficacy from ezetimibe. The prescribing clinician should confirm that vaginal administration meets the patient's specific clinical indication, particularly if the purpose is endometrial protection in a woman with a uterus on systemic estrogen.

Special Populations

Older Women (Age Over 65)

Women over 65 taking ezetimibe for established cardiovascular disease prevention and progesterone for continued HRT represent a growing clinical cohort. Polypharmacy is common in this group, and each added medication increases the risk of compounding sedation. The American Geriatrics Society 2023 Beers Criteria does not list ezetimibe as a potentially inappropriate medication for older adults, and oral progesterone appears on the list with a caution for increased risk of falls related to sedation [11]. Clinicians prescribing this combination in women over 65 should assess fall risk at baseline and at each follow-up.

Women With Concurrent Statin Use

Most women taking ezetimibe also take a statin, given the additive LDL-C lowering documented in IMPROVE-IT [8]. Statins metabolized by CYP3A4 (atorvastatin, simvastatin, lovastatin) theoretically share a metabolic pathway with oral progesterone, but clinical evidence for a meaningful statin-progesterone PK interaction at standard HRT doses is lacking. The more practical concern in this triple-drug scenario is patient-reported myalgia, which occurs in 5-10% of statin users and may be misattributed to progesterone or ezetimibe if a systematic symptom review is not performed.

Women With Gallbladder Disease

Ezetimibe's mechanism of reducing intestinal cholesterol absorption may increase biliary cholesterol saturation, a theoretical concern for cholelithiasis. The FDA label notes that cholelithiasis has been reported with ezetimibe, though a causal relationship is not established [1]. Estrogen-containing HRT is an independent risk factor for gallstone formation. Oral progesterone's net effect on bile composition has not been systematically studied, but progesterone's known ability to reduce gallbladder motility may compound this risk. Women with a history of gallstones or cholecystitis on this combination warrant discussion of these overlapping mechanistic risks.